-
Je něco špatně v tomto záznamu ?
Expression profile of miR-17/92 cluster is predictive of treatment response in rectal cancer
J. Kral, V. Korenkova, V. Novosadova, L. Langerova, M. Schneiderova, V. Liska, M. Levy, V. Veskrnova, J. Spicak, A. Opattova, K. Jiraskova, V. Vymetalkova, P. Vodicka, J. Slyskova,
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem
Grantová podpora
NV17-30920A
MZ0
CEP - Centrální evidence projektů
Digitální knihovna NLK
Plný text - Článek
NLK
Free Medical Journals
od 1996 do Před 1 rokem
Open Access Digital Library
od 1996-01-01
Medline Complete (EBSCOhost)
od 1996-01-01 do Před 1 rokem
PubMed
30277504
DOI
10.1093/carcin/bgy100
Knihovny.cz E-zdroje
- MeSH
- antitumorózní látky terapeutické užití MeSH
- lidé MeSH
- mikro RNA genetika MeSH
- nádorové biomarkery genetika MeSH
- nádorové buněčné linie MeSH
- nádory rekta farmakoterapie genetika mortalita MeSH
- proliferace buněk genetika MeSH
- regulace genové exprese u nádorů genetika MeSH
- stanovení celkové genové exprese MeSH
- výsledek terapie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
MicroRNA (miRNA) profiling represents a promising source of cancer-related biomarkers. miRNA signatures are specific for each cancer type and subgroups of patients with diverse treatment sensitivity. Yet this miRNA potential has not been satisfactorily explored in rectal cancer (RC). The aim of the study was to identify the specific miRNA signature with clinical and therapeutic relevance for RC. Expressions of 2555 miRNA were examined in 20 pairs of rectal tumors and matched non-malignant tissues by 3D-Gene Toray microarray. Candidate miRNAs were validated in an independent cohort of 100 paired rectal tissues and in whole plasma and exosomes of 100 RC patients. To study the association of miRNA profile with therapeutic outcomes, plasma samples were taken repeatedly over a time period of 1 year reflecting thus patients' treatment responses. Finally, the most prominent miRNAs were investigated in vitro for their involvement in cell growth. We identified RC-specific miRNA signature that distinguishes responders from non-responders to adjuvant chemotherapy. A predominant part of identified miRNAs was represented by the members of miR-17/92 cluster. Upregulation of miRNA-17, -18a, -18b, -19a, -19b, -20a, -20b and -106a in tumor was associated with higher risk of tumor relapse and their overexpression in RC cell lines stimulated cellular proliferation. Examination of these miRNAs in plasma exosomes showed that their levels differed between RC patients and healthy controls and correlated with patient's treatment response. miRNAs from miR-17/92 cluster represent a non-invasive biomarker to predict posttreatment prognosis in RC patients.
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19028176
- 003
- CZ-PrNML
- 005
- 20190822094103.0
- 007
- ta
- 008
- 190813s2018 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1093/carcin/bgy100 $2 doi
- 035 __
- $a (PubMed)30277504
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Kral, Jan $u Department of the Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Prague, Czech Republic. Department of Gastroenterology and Hepatology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
- 245 10
- $a Expression profile of miR-17/92 cluster is predictive of treatment response in rectal cancer / $c J. Kral, V. Korenkova, V. Novosadova, L. Langerova, M. Schneiderova, V. Liska, M. Levy, V. Veskrnova, J. Spicak, A. Opattova, K. Jiraskova, V. Vymetalkova, P. Vodicka, J. Slyskova,
- 520 9_
- $a MicroRNA (miRNA) profiling represents a promising source of cancer-related biomarkers. miRNA signatures are specific for each cancer type and subgroups of patients with diverse treatment sensitivity. Yet this miRNA potential has not been satisfactorily explored in rectal cancer (RC). The aim of the study was to identify the specific miRNA signature with clinical and therapeutic relevance for RC. Expressions of 2555 miRNA were examined in 20 pairs of rectal tumors and matched non-malignant tissues by 3D-Gene Toray microarray. Candidate miRNAs were validated in an independent cohort of 100 paired rectal tissues and in whole plasma and exosomes of 100 RC patients. To study the association of miRNA profile with therapeutic outcomes, plasma samples were taken repeatedly over a time period of 1 year reflecting thus patients' treatment responses. Finally, the most prominent miRNAs were investigated in vitro for their involvement in cell growth. We identified RC-specific miRNA signature that distinguishes responders from non-responders to adjuvant chemotherapy. A predominant part of identified miRNAs was represented by the members of miR-17/92 cluster. Upregulation of miRNA-17, -18a, -18b, -19a, -19b, -20a, -20b and -106a in tumor was associated with higher risk of tumor relapse and their overexpression in RC cell lines stimulated cellular proliferation. Examination of these miRNAs in plasma exosomes showed that their levels differed between RC patients and healthy controls and correlated with patient's treatment response. miRNAs from miR-17/92 cluster represent a non-invasive biomarker to predict posttreatment prognosis in RC patients.
- 650 _2
- $a antitumorózní látky $x terapeutické užití $7 D000970
- 650 _2
- $a nádorové biomarkery $x genetika $7 D014408
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a proliferace buněk $x genetika $7 D049109
- 650 _2
- $a stanovení celkové genové exprese $7 D020869
- 650 _2
- $a regulace genové exprese u nádorů $x genetika $7 D015972
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mikro RNA $x genetika $7 D035683
- 650 _2
- $a nádory rekta $x farmakoterapie $x genetika $x mortalita $7 D012004
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Korenkova, Vlasta $u Laboratory of Gene Expression, Institute of Biotechnology of the Czech Academy of Sciences, Vestec, Czech Republic.
- 700 1_
- $a Novosadova, Vendula $u Laboratory of Transgenic Models of Diseases, Czech Centre for Phenogenomics, Institute of Molecular Genetics of the Czech Academy of Sciences, Division BIOCEV, Vestec, Czech Republic.
- 700 1_
- $a Langerova, Lucie $u Laboratory of Gene Expression, Institute of Biotechnology of the Czech Academy of Sciences, Vestec, Czech Republic.
- 700 1_
- $a Schneiderova, Michaela $u Department of Surgery, General University Hospital, Prague, Czech Republic.
- 700 1_
- $a Liska, Vaclav $u Department of Surgery, Teaching Hospital and Medical School of Charles University, Pilsen, Czech Republic. Biomedical Centre, Faculty of Medicine in Pilsen, Charles University in Prague, Pilsen, Czech Republic.
- 700 1_
- $a Levy, Miroslav $u Department of Surgery, First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic.
- 700 1_
- $a Veskrnova, Veronika $u Department of Oncology, First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic.
- 700 1_
- $a Spicak, Julius $u Department of Gastroenterology and Hepatology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
- 700 1_
- $a Opattova, Alena $u Department of the Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Prague, Czech Republic. Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic.
- 700 1_
- $a Jiraskova, Katerina $u Department of the Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Prague, Czech Republic. Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic.
- 700 1_
- $a Vymetalkova, Veronika $u Department of the Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Prague, Czech Republic. Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic.
- 700 1_
- $a Vodicka, Pavel $u Department of the Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Prague, Czech Republic. Biomedical Centre, Faculty of Medicine in Pilsen, Charles University in Prague, Pilsen, Czech Republic. Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic.
- 700 1_
- $a Slyskova, Jana $u Department of the Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Prague, Czech Republic.
- 773 0_
- $w MED00001050 $t Carcinogenesis $x 1460-2180 $g Roč. 39, č. 11 (2018), s. 1359-1367
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30277504 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190813 $b ABA008
- 991 __
- $a 20190822094341 $b ABA008
- 999 __
- $a ok $b bmc $g 1433325 $s 1066636
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 39 $c 11 $d 1359-1367 $e 20181213 $i 1460-2180 $m Carcinogenesis $n Carcinogenesis $x MED00001050
- GRA __
- $a NV17-30920A $p MZ0
- LZP __
- $a Pubmed-20190813
